KNSA News and Press, Kiniksa Pharmaceuticals Ltd. From 01/04/24

– ARCALYST ® (rilonacept) 2023 net product revenue grew ~90% year-over-year to $233.1 million (unaudited) – – ARCALYST 2024 net product revenue expected to be $360 - $380 million – – Abiprubart (KPL-404) Phase 2 rheumatoid arthri...

HAMILTON, Bermuda, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). A live web...

2023-12-16 12:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-03 11:07:17 ET Summary Kiniksa Pharmaceuticals delivered another good quarter with Arcalyst, although the revenue beat was partially driven by an inventory benefit. The launch metrics for Arcalyst have improved slightly, with an increase in prescribers and repeat patients....

2023-10-31 14:35:20 ET Kiniksa Pharmaceuticals Ltd (KNSA) Q3 2023 Earnings Conference Call October 31, 2023 08:30 AM ET Company Participants Rachel Frank - Associate Director, IR Sanj Patel - CEO Ross Moat - SVP and CCO Mark Ragosa - SVP and CFO John Paol...

2023-10-31 07:44:41 ET More on Kiniksa Pharmaceuticals Kiniksa's Diversified Pipeline Augments Arcalyst Potential Seeking Alpha’s Quant Rating on Kiniksa Pharmaceuticals Historical earnings data for Kiniksa Pharmaceuticals Financial information for Kin...

– ARCALYST ® (rilonacept) Q3 2023 net product revenue of $64.8 million, representing ~94% year-over-year growth – – KPL-404 Phase 2 rheumatoid arthritis data from Cohorts 1-3 now expected in Q1 2024 – – Cash reserves of $201 mi...

Tennant Company (TNC) is expected to report for Q3 2023 Stellantis N.V. (STLA) is expected to report for Q3 2023 Marathon Petroleum Corporation (MPC) is expected to report $7.79 for Q3 2023 Easterly Government Properties Inc. (DEA) is expected to report $0.29 for Q3 2023 Allegion ...

Kiniksa Pharmaceuticals Ltd. (KNSA) is expected to report $-0.18 for Q3 2023

2023-10-30 11:27:11 ET More on Kiniksa Pharmaceuticals Kiniksa's Diversified Pipeline Augments Arcalyst Potential Seeking Alpha’s Quant Rating on Kiniksa Pharmaceuticals Historical earnings data for Kiniksa Pharmaceuticals Financial information for Kin...